Related Experiment Video

Updated: May 18, 2026

Development and Application of Rapamycin-regulated Tyrosine Phosphatases
06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

The expression of URGCP gene in prostate cancer cell lines: correlation with rapamycin

Yavuz Dodurga1, Cığır Biray Avcı, Sunde Yılmaz Susluer

  • 1Department of Medical Biology, Pamukkale University School of Medicine, Denizli, Turkey. yavuzdodurga@gmail.com

Molecular Biology Reports
|September 26, 2012
PubMed

Insights

Rapamycin (RPM) affects prostate cancer cell viability and URGCP gene expression. RPM significantly decreased URGCP gene expression in DU145 and PC3 cell lines, indicating its potential role in prostate cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Prostate cancer has limited therapeutic options.
  • Rapamycin (RPM) inhibits cell cycle progression.
  • URGCP (upregulator of cell proliferation) is a novel gene implicated in cell growth.

Purpose of the Study:

  • To investigate the effect of Rapamycin (RPM) on URGCP gene expression in prostate cancer cell lines (PC3, DU145, LNCAP).
  • To evaluate the cytotoxic effects and dose-dependent response of RPM in these cell lines.

Main Methods:

  • Cell viability and cytotoxicity assessed using Trypan blue dye exclusion and XTT assays over three days.
  • URGCP gene expression levels analyzed in RPM-treated and control prostate cancer cell lines.
  • Half maximal inhibitory concentration (IC50) determined for RPM.

Main Results:

  • RPM exhibited time- and dose-dependent cytotoxic effects in DU145, PC3, and LNCAP cells, with IC50 values ranging from 1-100 nM.
  • Specific IC50 values were 10 nM for DU145, 25 nM for PC3, and 50 nM for LNCaP.
  • URGCP gene expression was significantly decreased in DU145 and PC3 cells upon RPM treatment compared to controls.

Conclusions:

  • Rapamycin demonstrates significant cytotoxic effects on prostate cancer cell lines.
  • RPM treatment leads to a notable decrease in URGCP gene expression in specific prostate cancer models.
  • These findings suggest a potential therapeutic role for RPM and highlight the involvement of URGCP in prostate cancer progression.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...